Sanford et al. demonstrate that a CCR2 antagonist (PF-04136309) can block the mobilization of CCR2+ monocytes from bone marrow to tumors in a mouse model of pancreatic cancer and can lead to TAM depletion, causing the inhibition of tumor growth and distant metastasis [58]. Here, CCR2 is linked to familial pancreatic carcinoma.